** Drugmaker Ionis Pharmaceuticals' IONS.O shares rise 4.5% to $33.40 premarket
** IONS posts Q4 sales of $227 mln, above analysts' est of $137.6 mln - LSEG
** Co reports Q4 loss of 66 cents/share vs analysts' est loss of $1.12/share - LSEG
** Co expects 2025 rev to be over $600 mln; analysts on avg expect 2025 rev to be $676 mln - LSEG
** As of December 31, 2024, IONS had cash, cash equivalents and short-term investments of $2.3 bln
** Co forecasts cash, cash equivalents and short-term investments of about $1.7 bln for 2025
** IONS fell ~34% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。